Journal Browser

► Journal Browser

Special Issue Information

Dear Colleagues,

The historically rapid development and deployment of COVID-19 vaccines exemplify the progress that has been achieved in both basic research and the manufacturing technology of vaccines during the past few decades, while a sobering fact is that effective vaccines against tough “bugs”, such as HIV and TB, are still lacking. In the meantime, vaccines against cancer, Alzheimer’s and allergic diseases are also earnestly pursued. To tackle these challenges, continuous efforts are required to explore new approaches and technologies for vaccine development.

Given that the immunogenicity and efficacy of vaccines are determined by both vaccine formulation and host factors, the aim of this Special Issue is to address scientific questions related to these aspects. All research articles, reviews, methodologies able to shed new light on improving antigen design, developing better adjuvants and more efficient delivery techniques, optimizing vaccination strategies and understanding host factors related to vaccine efficacy are welcome. Studies/reviews focused on mucosal vaccine development are also included.

We look forward to receiving your contributions.

Prof. Dr. Yanmin Wan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

antigen design
adjuvant
vaccination strategy
vaccine effect
immunogenicity
mucosal immunity
recombinant vector vaccine
delivery technique

Published Papers (2 papers)

Download All Papers

Research

Open AccessArticle

Evaluation of the Immunomodulatory Effect of the Recombinant 14-3-3 and Major Antigen Proteins of Strongyloides stercoralis against an Infection by S. venezuelensis

Liz F. Sánchez-Palencia

and

Vaccines 2022, 10(8), 1292; https://doi.org/10.3390/vaccines10081292 - 10 Aug 2022

Viewed by 986

Abstract

Strongyloidiasis, caused by Strongyloides stercoralis, is a neglected parasitic disease that represents a serious public health problem. In immunocompromised patients, this parasitosis can result in hyperinfection or disseminated disease with high levels of mortality. In previous studies, the mRNAs encoding for the 14-3-3 and major antigen proteins were found to be expressed at high levels in S. stercoralis L3 larvae, suggesting potential key roles in parasite-host interactions. We have produced them as recombinant proteins (rSs14-3-3 and rSsMA) in a bacterial protein expression system. The serum levels of anti-rSs14-3-3 and anti-rSsMA IgGs are increased upon infection with S. venezuelensis, validating the use of the mouse model since the native 14-3-3 and MA proteins induce an immune response. Each recombinant protein was formulated in the adjuvant adaptation (ADAD) vaccination system and injected twice, subcutaneously, in CD1 mice that were experimentally infected with 3000 S. venezuelensis L3 to evaluate their protective and immunomodulatory activity. Our results, including the number of parthenogenetic females, number of eggs in stool samples and the analysis of the splenic and intestinal indexes, show that the vaccines did not protect against infection. The immunization with rSs14-3-3 induced changes in the cytokine profile in mice, producing higher expression of IL-10, TGF-β, IL-13 and TNF-α in the spleen, suggesting a Th2/Treg-type response with an increase in TNF-α levels, confirming its role as an immunomodulator. Full article

(This article belongs to the Special Issue Advance in Vaccine Development)

► Show Figures

Figure 1

Open AccessArticle

Immune Correlates of Disseminated BCG Infection in IL12RB1-Deficient Mice

and

Vaccines 2022, 10(7), 1147; https://doi.org/10.3390/vaccines10071147 - 19 Jul 2022

Viewed by 972

Abstract

Interleukin-12 receptor β1 (IL12RB1)-deficient individuals show increased susceptibilities to local or disseminated BCG infection and environmental mycobacteria infection. However, the low clinical penetrance of IL12RB1 deficiency and low recurrence rate of mycobacteria infection suggest that protective immunity still exists in this population. In this study, we investigated the mechanism of tuberculosis suppression using the IL12RB1-deficient mouse model. Our results manifested that Il12rb1^−/− mice had significantly increased CFU counts in spleens and lungs, especially when BCG (Danish strain) was inoculated subcutaneously. The innate TNF-a and IFN-γ responses decreased, while the IL-17 responses increased significantly in the lungs of Il12rb1^−/− mice. We also found that PPD-specific IFN-γ release was impaired in Il12rb1^−/− mice, but the specific TNF-a release was not compromised, and the antibody responses were significantly enhanced. Moreover, correlation analyses revealed that both the innate and PPD-specific IFN-γ responses positively correlated with CFU counts, whereas the innate IL-12a levels negatively correlated with CFU counts in Il12rb1^−/− mice lungs. Collectively, these findings proved that the adaptive immunities against mycobacteria are not completely nullified in Il12rb1^−/− mice. Additionally, our results imply that IFN-γ responses alone might not be able to contain BCGitis in the setting of IL12RB1 deficiency. Full article

(This article belongs to the Special Issue Advance in Vaccine Development)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Special Issue "Advance in Vaccine Development"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (2 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI